BridgeBio Pharma (BBIO) Total Non-Current Liabilities (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Total Non-Current Liabilities data on file, last reported at $3.6 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 44.43% year-over-year to $3.6 billion; the trailing twelve-month figure through Mar 2026 stood at $3.6 billion (up 44.43% YoY), and the FY2025 full-year result was $3.0 billion, up 26.75% from the prior year.
• Total Non-Current Liabilities advanced to $3.6 billion in Q1 2026, from $3.0 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $3.6 billion in Q1 2026 to a low of $1.8 billion in Q1 2023.
• A 5-year average of $2.2 billion and a median of $1.9 billion in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities decreased 0.81% in 2022 and jumped 55.09% in 2025, its largest moves.
• Tracing BBIO's Total Non-Current Liabilities over 5 years: stood at $1.8 billion in 2022, then grew by 2.28% to $1.9 billion in 2023, then increased by 26.2% to $2.4 billion in 2024, then advanced by 26.75% to $3.0 billion in 2025, then grew by 20.82% to $3.6 billion in 2026.
• Business Quant data shows BBIO's Total Non-Current Liabilities at $3.6 billion in Q1 2026, $3.0 billion in Q4 2025, and $2.9 billion in Q3 2025.